---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004601"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:18:47.530088+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing

## Summary
- Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.
- Phase 1/1b BP1001-A in solid tumors advanced to second dose level; Phase 1b with paclitaxel planned.
- Phase 1/1b BP1002 in relapsed/refractory AML enrolling at 40 mg/m2; no DLTs at 20 mg/m2.
- Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort (40 mg/m2) after no DLTs.
- Patent portfolio: 5 US and 53 foreign issued patents covering DNAbilize technology.

## SEC filing metadata
- accession: 0001558370-24-004601
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/0001558370-24-004601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/bpth-20240402x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004601
- JSON: https://secwatch.observer/filing/0001558370-24-004601.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.